Veraxa Biotech AG - Post de-SPAC (VRXA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.11, +0.91% vs the prior close of $1.10.
- Volume 125.38K shares, 0.4x its 50-day average (light).
- New SEC filings: 6-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
VRXA rises 0.9% to $1.11. Closed at $1.11, +0.91% vs the prior close of $1.10. Day range $1.08–$1.15, opened at $1.15.
VRXA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VRXA rises 0.9% to $1.11
- Closed at $1.11, +0.91% vs the prior close of $1.10. Day range $1.08–$1.15, opened at $1.15.
- Volume was 125.38K shares, 0.4x its 50-day average of 283.67K — lighter than usual.
- Price is -25.9% vs its 50-day average ($1.50) and -85.1% vs its 200-day average ($7.45).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 95.9% below the 52-week high.
Oct 15, 2026 — VRXA dips 0.9% to $1.10
- Closed at $1.10, -0.90% vs the prior close of $1.11. Day range $1.06–$1.15, opened at $1.13.
- Volume was 114.50K shares, 0.4x its 50-day average of 283.38K — lighter than usual.
- Price is -27.3% vs its 50-day average ($1.51) and -85.3% vs its 200-day average ($7.49).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 96.0% below the 52-week high.
- SEC filings that day: 6-K.
Oct 14, 2026 — VRXA slides 7.5% to $1.11
- Closed at $1.11, -7.50% vs the prior close of $1.20. Day range $1.08–$1.20, opened at $1.20.
- Volume was 61.50K shares, 0.2x its 50-day average of 285.15K — lighter than usual.
- Price is -27.3% vs its 50-day average ($1.53) and -85.3% vs its 200-day average ($7.54).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 95.9% below the 52-week high.
Oct 13, 2026 — VRXA jumps 5.3% to $1.20 on 2.7x normal volume
- Closed at $1.20, +5.26% vs the prior close of $1.14. Day range $1.12–$1.35, opened at $1.20.
- Volume was 741.30K shares, 2.7x its 50-day average of 272.11K — unusually heavy trading.
- Price is -22.1% vs its 50-day average ($1.54) and -84.2% vs its 200-day average ($7.59).
- 52-week range $1.04–$27.36; today's close sits at 1% of that range, 95.6% below the 52-week high.
Oct 12, 2026 — VRXA slides 9.5% to $1.14
- Closed at $1.14, -9.52% vs the prior close of $1.26. Day range $1.13–$1.30, opened at $1.22.
- Volume was 156.10K shares, 0.6x its 50-day average of 275.21K — lighter than usual.
- Price is -26.6% vs its 50-day average ($1.55) and -85.1% vs its 200-day average ($7.64).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 95.8% below the 52-week high.
Oct 9, 2026 — VRXA jumps 15.6% to $1.26 on 7.8x normal volume
- Closed at $1.26, +15.60% vs the prior close of $1.09. Day range $1.07–$1.41, opened at $1.08.
- Volume was 1.86M shares, 7.8x its 50-day average of 239.81K — unusually heavy trading.
- Price is -19.5% vs its 50-day average ($1.57) and -83.6% vs its 200-day average ($7.68).
- 52-week range $1.04–$27.36; today's close sits at 1% of that range, 95.4% below the 52-week high.
Oct 8, 2026 — VRXA slides 9.2% to $1.09
- Closed at $1.09, -9.17% vs the prior close of $1.20. Day range $1.09–$1.21, opened at $1.19.
- Volume was 211.90K shares, 0.9x its 50-day average of 239.13K.
- Price is -31.0% vs its 50-day average ($1.58) and -85.9% vs its 200-day average ($7.73).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 96.0% below the 52-week high.
Oct 7, 2026 — VRXA jumps 11.1% to $1.20 on 3.3x normal volume
- Closed at $1.20, +11.11% vs the prior close of $1.08. Day range $1.10–$1.32, opened at $1.16.
- Volume was 749.20K shares, 3.3x its 50-day average of 230.40K — unusually heavy trading.
- Price is -24.9% vs its 50-day average ($1.60) and -84.6% vs its 200-day average ($7.78).
- 52-week range $1.04–$27.36; today's close sits at 1% of that range, 95.6% below the 52-week high.
Oct 6, 2026 — VRXA slides 4.4% to $1.08, a 52-week low, 8 down days in a row
- Closed at $1.08, -4.42% vs the prior close of $1.13. Day range $1.04–$1.15, opened at $1.12.
- Volume was 395.30K shares, 1.7x its 50-day average of 238.88K.
- Price is -33.0% vs its 50-day average ($1.61) and -86.2% vs its 200-day average ($7.82).
- 52-week range $1.04–$27.36; today's close sits at 0% of that range, 96.1% below the 52-week high.
- That makes 8 straight losses.
Oct 5, 2026 — VRXA ends flat (+0.0%) to $1.13, 7 down days in a row
- Closed at $1.13, +0.00% vs the prior close of $1.13. Day range $1.12–$1.16, opened at $1.13.
- Volume was 153.20K shares, 0.6x its 50-day average of 239.35K.
- Price is -30.7% vs its 50-day average ($1.63) and -85.6% vs its 200-day average ($7.87).
- 52-week range $1.11–$27.36; today's close sits at 0% of that range, 95.9% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — VRXA slides 5.0% to $1.13, a 52-week low, 6 down days in a row
- Closed at $1.13, -5.04% vs the prior close of $1.19. Day range $1.11–$1.15, opened at $1.15.
- Volume was 150.20K shares, 0.6x its 50-day average of 243.33K.
- Price is -31.3% vs its 50-day average ($1.65) and -85.7% vs its 200-day average ($7.92).
- 52-week range $1.11–$27.36; today's close sits at 0% of that range, 95.9% below the 52-week high.
- That makes 6 straight losses.
VRXA latest news & SEC filings
Every SEC filing by or about VRXA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 4, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 4, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 4, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Baumann Oliver Rolf bought 50,000 shares at $1.50 (≈$75.00K) on Aug 27, 2026
- Baumann Oliver Rolf bought 50,000 shares at $1.50 (≈$75.00K) on Aug 27, 2026
- Baumann Oliver Rolf bought 50,000 shares at $1.50 (≈$75.00K) on Aug 27, 2026
- Baumann Oliver Rolf bought 50,000 shares at $1.50 (≈$75.00K) on Aug 27, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Antz Christoph Rudiger bought 5,000 shares at $1.53 (≈$7.65K) on Aug 27, 2026
- Antz Christoph Rudiger bought 5,000 shares at $1.53 (≈$7.65K) on Aug 27, 2026
- Antz Christoph Rudiger bought 5,000 shares at $1.53 (≈$7.65K) on Aug 27, 2026
- Antz Christoph Rudiger bought 5,000 shares at $1.53 (≈$7.65K) on Aug 27, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 20, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 10, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade VRXA
- How much it moves: over the last 20 sessions the average daily move was 4.62% (largest 15.6%). That is a volatile stock.
- Liquidity: about 261.81K shares (≈$290.61K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.11 vs a range of $1.04–$27.36 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Christoph Rudiger Antz bought 5,000 shares on Aug 27, 2026.
- Latest filings: 6-K Oct 15, 2026; 6-K Sep 4, 2026; 6-K Aug 24, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VRXA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.15 | 1.15 | 1.08 | 1.11 | 125.38K |
| Oct 15, 2026 | 1.13 | 1.15 | 1.06 | 1.10 | 114.50K |
| Oct 14, 2026 | 1.20 | 1.20 | 1.08 | 1.11 | 61.50K |
| Oct 13, 2026 | 1.20 | 1.35 | 1.12 | 1.20 | 741.30K |
| Oct 12, 2026 | 1.22 | 1.30 | 1.13 | 1.14 | 156.10K |
| Oct 9, 2026 | 1.08 | 1.41 | 1.07 | 1.26 | 1.86M |
| Oct 8, 2026 | 1.19 | 1.21 | 1.09 | 1.09 | 211.90K |
| Oct 7, 2026 | 1.16 | 1.32 | 1.10 | 1.20 | 749.20K |
| Oct 6, 2026 | 1.12 | 1.15 | 1.04 | 1.08 | 395.30K |
| Oct 5, 2026 | 1.13 | 1.16 | 1.12 | 1.13 | 153.20K |
| Oct 2, 2026 | 1.15 | 1.15 | 1.11 | 1.13 | 150.20K |
| Oct 1, 2026 | 1.25 | 1.25 | 1.18 | 1.19 | 64.90K |
| Sep 30, 2026 | 1.31 | 1.31 | 1.17 | 1.25 | 119.50K |
| Sep 29, 2026 | 1.37 | 1.37 | 1.30 | 1.31 | 52.80K |
| Sep 28, 2026 | 1.43 | 1.44 | 1.36 | 1.37 | 48.50K |
| Sep 25, 2026 | 1.43 | 1.45 | 1.38 | 1.41 | 55.80K |
| Sep 24, 2026 | 1.37 | 1.44 | 1.37 | 1.41 | 23.30K |
| Sep 23, 2026 | 1.44 | 1.44 | 1.38 | 1.39 | 43.40K |
| Sep 22, 2026 | 1.42 | 1.44 | 1.36 | 1.41 | 59.50K |
| Sep 21, 2026 | 1.45 | 1.52 | 1.42 | 1.42 | 49.10K |
About Veraxa Biotech AG - Post de-SPAC
Veraxa Biotech AG - Post de-SPAC (VRXA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in ZURICH. State of incorporation: Switzerland. Fiscal year ends December 31. SEC CIK 2079109.
VRXA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christoph Rudiger Antz | Chief Executive Officer | Aug 31, 2026 |
| Oliver Rolf Baumann | Director | Aug 31, 2026 |
| Marc Gruninger | Director | Jun 10, 2026 |
| Warren Hosseinion | Director | Jun 9, 2026 |
| Christoph Samuel Ziegler | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christoph Rudiger Antz | Chief Executive Officer | Aug 31, 2026 |
| Torsten Georg Friedrich Buergermeister | Chief Financial Officer | Jun 9, 2026 |
| Heinz Schwer | Chief Business Officer | Jun 9, 2026 |
| Raju Sudir Willener | Chief Financial Officer | Sep 14, 2026 |
| Halem Carl Von | Interim CFO | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 27, 2026 | Christoph Rudiger Antz | Buy | 5,000 | $1.53 |
| Aug 27, 2026 | Christoph Rudiger Antz | Buy | 5,000 | $1.53 |
| Aug 27, 2026 | Christoph Rudiger Antz | Buy | 5,000 | $1.53 |
| Aug 27, 2026 | Christoph Rudiger Antz | Buy | 5,000 | $1.53 |
| Aug 27, 2026 | Oliver Rolf Baumann | Buy | 50,000 | $1.50 |
| Aug 27, 2026 | Oliver Rolf Baumann | Buy | 50,000 | $1.50 |
| Aug 27, 2026 | Oliver Rolf Baumann | Buy | 50,000 | $1.50 |
| Aug 27, 2026 | Oliver Rolf Baumann | Buy | 50,000 | $1.50 |
VRXA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
VRXA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VRXA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.